Chaston Timothy B, Watts Ralph N, Yuan Jun, Richardson Des R
Children's Cancer Institute Australia for Medical Research, Iron Metabolism and Chelation Program, Sydney, New South Wales, Australia.
Clin Cancer Res. 2004 Nov 1;10(21):7365-74. doi: 10.1158/1078-0432.CCR-04-0865.
The development of novel and potent iron chelators as clinically useful antitumor agents is an area of active interest. Antiproliferative activity of chelators often relates to iron deprivation or stimulation of iron-dependent free radical damage. Recently, we showed that novel iron chelators of the di-2-pyridylketone isonicotinoyl hydrazone (PKIH) class have potent and selective antineoplastic activity (E. Becker, et al., Br. J. Pharmacol., 138: 819-30, 2003). In this study, we assessed the effects of the PKIH analogues on the redox activity of iron in terms of understanding their antitumor activity.
We tested the PKIH analogues for their ability to promote iron-mediated ascorbate oxidation, benzoate hydroxylation, and plasmid degradation. Subsequent experiments assessed their ability to bind DNA, inhibit topoisomerase I, and cause DNA damage. To measure intracellular reactive oxygen species, we used the redox-sensitive probe, 2',7'-dichloro-fluorescein-diacetate, to measure intracellular PKIH-dependent redox activity.
The PKIH analogues had relatively little effect on ascorbate oxidation in the presence of Fe(III) but stimulated benzoate hydroxylation and plasmid DNA degradation in the presence of Fe(II) and H2O2. These ligands could not inhibit DNA topoisomerase I or cause DNA damage in intact cells. PKIH markedly increased the intracellular generation of reactive oxygen species, and this was inhibited by catalase. This enzyme also decreased the antiproliferative effect of PKIH, indicating H2O2 played a role in its cytotoxic activity.
Our results suggest that the antiproliferative effects of these chelators relates to intracellular iron chelation, followed by the stimulation of iron-mediated free radical generation via the so-formed iron complex.
开发新型高效的铁螯合剂作为临床可用的抗肿瘤药物是一个备受关注的领域。螯合剂的抗增殖活性通常与铁缺乏或铁依赖性自由基损伤的刺激有关。最近,我们发现二 - 2 - 吡啶酮异烟酰腙(PKIH)类新型铁螯合剂具有强大的选择性抗肿瘤活性(E. 贝克尔等人,《英国药理学杂志》,138: 819 - 30,2003)。在本研究中,我们从了解其抗肿瘤活性的角度评估了PKIH类似物对铁氧化还原活性的影响。
我们测试了PKIH类似物促进铁介导的抗坏血酸氧化、苯甲酸羟化和质粒降解的能力。后续实验评估了它们结合DNA、抑制拓扑异构酶I和引起DNA损伤的能力。为了测量细胞内活性氧,我们使用氧化还原敏感探针2',7'-二氯荧光素二乙酸酯来测量细胞内PKIH依赖性氧化还原活性。
PKIH类似物在Fe(III)存在下对抗坏血酸氧化的影响相对较小,但在Fe(II)和H2O2存在下刺激了苯甲酸羟化和质粒DNA降解。这些配体不能抑制完整细胞中的DNA拓扑异构酶I或引起DNA损伤。PKIH显著增加了细胞内活性氧的产生,而过氧化氢酶可抑制这一现象。该酶也降低了PKIH的抗增殖作用,表明H2O2在其细胞毒性活性中起作用。
我们的结果表明,这些螯合剂的抗增殖作用与细胞内铁螯合有关,随后通过形成的铁络合物刺激铁介导的自由基生成。